Duratears

Quick links to important sections

Duratears

Method of action: Ophthalmologicals

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duratears

Quick Facts

Property Description
Active Ingredients Dextran 70, Hypromellose
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Artificial Tears, Ocular Lubricants
Common Use Temporary relief of minor ocular irritation
Origin Semisynthetic Polymers

What Type of Medicine is Duratears and How is it Classified?

The medicinal preparation containing the polymers Dextran 70 and Hypromellose is classified as an Ocular Lubricant Solution, belonging to the Pharmacological Class of Artificial Tears. This widely accessible product is a non-prescription Human Over-the-Counter Drug intended solely for Topical Ophthalmic Application to the external surface of the eye. Its classification as a lubricant is consistently recognized by health authorities, confirming its primary role is physical protection rather than pharmacological action.

Composition: A Differentiated Polymer Combination

This ophthalmic preparation stands out as a Combination Product, utilizing the specific pairing of Dextran 70 and Hypromellose (Hydroxypropyl methylcellulose), suspended in a sterile Aqueous Vehicle. Both are Semisynthetic polymers. The dual composition provides a key point of differentiation: while Hypromellose enhances the solution's viscosity, Dextran 70 contributes unique surface-active properties essential for mechanical film stabilization. Other products, such as Tears Naturale, utilize this same specific combination of polymers to achieve their lubricating effect.

General Purpose of Ocular Lubricants

The general purpose of applying this solution is to maintain and stabilize the moisture barrier on the exposed eye surface, a necessary action often required due to environmental factors or visual stress. By promoting effective Corneal Wetting and increasing the solution's viscosity, the preparation forms a protective film that significantly delays the natural breakdown of the tear film. This mechanism helps alleviate the common symptoms of dryness and Minor Ocular Irritations by reducing friction and providing a temporary surface substitute for deficient natural tears.

What side effects are possible with Duratears?

Possible side effects and safety information

The official safety documentation for ophthalmic solutions containing the polymers Dextran 70 and Hypromellose organizes adverse reactions primarily around local effects and the potential for allergic sensitivity. The majority of reported events are classified as having an Unknown Frequency, meaning their occurrence rate cannot be reliably estimated from available regulatory data.

System-Organ Class Adverse Reactions

The officially listed possible adverse reactions are chiefly categorized under Eye Disorders. These local effects may include sensations such as ocular irritation, ocular pain, itching (pruritus), and hyperaemia of the eye (redness). A common experience documented in regulatory sources is blurred vision, which is noted to be transient (temporary), often occurring immediately following application.

Secondary concerns are classified under Immune System Disorders related to potential hypersensitivity.

Safety Restrictions and Serious Reactions

The most significant safety constraint documented in regulatory labeling is the contraindication for individuals with a known hypersensitivity or allergy to Dextran 70, Hypromellose, or any other component of the formulation. Although rare, the possibility of serious hypersensitivity reactions (allergic reactions) is listed as a potential safety event.

Regulatory documents for this product type typically do not list specific safety considerations for older adults or individuals with renal or hepatic impairment.

This classification approach ensures that the primary safety focus remains on local ocular adverse events and the constraint related to known component allergies.

Overdose and Emergency Response

The official regulatory documentation for the Dextran 70/Hypromellose ophthalmic solution defines the overdose profile based on the route of exposure. Due to its topical application and non-systemic components, an overdose from the intended use is not expected to be dangerous, and no case of topical overdose has been reported in regulatory labeling.

For managing local topical excess, the official guidance provides a clear procedural step: the product can be easily washed out of the eye with lukewarm tap water.

The official profile mandates specific emergency actions primarily related to accidental swallowing or ingestion. If this occurs, the first required step is to immediately contact a Poison Control Center. Urgent medical attention is explicitly required when ingestion leads to serious symptoms affecting systemic functions, such as passing out or developing trouble breathing. In these scenarios, regulatory documents state that users must call 911 or local emergency services.

Consistent with the product's classification, no specific antidote is documented or known for this overdose scenario. The official statements emphasize the required emergency protocols necessary to manage severe systemic symptoms following ingestion, and the local procedure for topical management, excluding any unverified clinical advice.

Therapeutic Uses of Duratears

What Duratears treats: main uses and benefits

The solution is commonly used to help with symptomatic relief for the eyes in situations where patients experience distressing symptoms linked to dryness. The product may be used as part of symptomatic management for the temporary relief of discomfort due to minor irritations of the eye.

The preparation is considered relevant for managing symptoms that interfere with daily comfort in conditions characterized by periods of heightened symptoms, which include tear film instability and mild-to-moderate dry eye disease. It is applied across domains where additional symptomatic support is needed to help address symptom clusters related to physical discomfort, such as burning, stinging, or the sensation of grittiness caused by dryness.

The solution may be relevant in contexts marked by increased discomfort due to external stressors, such as exposure to wind, sun, or extended screen time. It is often used when symptoms intensify, and may assist with short-term symptomatic assistance that supports patients during difficult episodes.

“This preparation may help ease distress related to moisture deficiency and assists with maintaining functional stability to support the patient during difficult episodes.”


Quick Fact: Key Use: Symptom Support for Ocular Discomfort

Property Description
Primary Use Context Temporary symptomatic relief of minor ocular irritation.
Symptom Type Addressed Symptoms related to physical discomfort, including burning, stinging, and grittiness.
Symptom Triggers External stressors (wind, sun, dry air) and symptoms that interfere with daily functioning.
Therapeutic Benefit Contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Regulatory References

  1. DailyMed Label for Dextran 70/Hypromellose Solution

Eligibility and Restrictions for Use

Who Can and Cannot Use Duratears?

This section explains the officially documented population eligibility rules for the Dextran 70/Hypromellose ophthalmic solution, as defined by regulatory labeling.


Eligibility Scope

Category Regulatory Status
Populations Allowed Adults, Children, and the Elderly are eligible for use.
Pregnancy/Lactation Use is permitted during both pregnancy and breastfeeding.
Contraindicated Populations Patients with known hypersensitivity to Dextran 70, Hypromellose, or any excipients.
Eligibility Restriction Soft contact lens wearers must remove lenses before application and wait at least 15 minutes before reinsertion.

Official Eligibility Summary

Regulatory documents define the eligibility profile of this ophthalmic lubricant as highly permissive due to its non-systemic nature. Use is considered acceptable for all age groups, including children, adults, and the elderly. The only absolute regulatory exclusion is the standard contraindication for documented component hypersensitivity. Furthermore, no specific eligibility limitations are required for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Property Official Regulatory Status (Dextran 70 / Hypromellose)
Medicinal product categories with documented interactions: Other Topical Ophthalmic Products (Physical Interference)
Specific interacting medicines (if explicitly listed): None explicitly listed by name; rule applies to any other topical eye medication.
Mechanistic basis of interactions (only if stated in label): Physical Interference (Timing-based; preventing wash-out or dilution of co-administered product).
Timing-based interaction rules (if applicable): Mandatory administration separation of at least five (5) minutes when used with another ophthalmic preparation.
Population-specific interaction notes (if applicable): None documented in regulatory labeling.

Resulting interaction structure

Official interaction statements:

  • No systemic drug-drug interactions involving metabolic enzymes (e.g., CYP) or drug transporters (e.g., P-gp) are documented in official regulatory prescribing information.
  • No formal contraindications resulting from interactions with medicinal products, food, alcohol, or supplements are documented.
  • The only documented interaction requirement is a physical administration rule involving co-administration with other topical ophthalmic medicinal products.
  • Official labeling requires that other topical eye preparations and this product must be administered with a mandatory time interval of at least five (5) minutes between applications.

Connection to the overall interaction profile (3 sentences): Official regulatory documents define the interaction structure of Duratears as lacking systemic drug-drug, drug-food, or drug-substance interactions due to its physical mechanism and minimal systemic exposure. The profile is limited to a single administrative constraint: a mandatory timing separation rule for co-administration with any other topical ophthalmic preparation. This constraint ensures the integrity of the ocular lubricant film and the proper physical action of the co-administered agent, as stipulated in government labeling.

Mechanism of Action

Physical Occlusion and Barrier Function

Duratears Ointment works by establishing a non-pharmacological, physical lipid barrier across the ocular surface. This passive mechanism acts at the air-tear film interface, providing a structural physical overlay on the corneal and conjunctival epithelial surfaces.

Retarding Excessive Evaporation

The occlusive lipid layer primarily functions to impede the diffusion of water vapor from the underlying aqueous tear film. By slowing this evaporative process, the mechanism assists in the stabilization of the aqueous tear phase and influences the concentration gradient at the ocular surface.

Surface Lubrication and Friction Modulation

The inherent viscosity and rheological properties of the oil-based formula provide a highly lubricious layer between the eyelid and the eye surface. This physical action reduces the coefficient of friction during the blinking process, resulting in the modulation of mechanical shearing forces on the epithelial layer.

Dosage and Administration Information

Duratears Lubricating Eye Ointment is used for the temporary relief of irritation and discomfort due to dry eye conditions. The ointment is typically administered as a thin ribbon to the affected eye(s), commonly at bedtime, or as directed by a healthcare professional.

Before application, wash your hands thoroughly to prevent contamination. If you wear contact lenses, you must remove them prior to application and wait for a period of time (usually 30 minutes, or as advised by your doctor) before reinserting them.

Application Steps

Step Instruction
1 Remove the cap from the tube.
2 Gently tilt your head back and pull your lower eyelid down with a clean finger to form a small pocket.
3 Hold the tube close to the eye without touching the tip to the eye, eyelid, or any other surface to maintain sterility.
4 Squeeze a thin ribbon of ointment (about 1 to 1.5 cm or 1/4 inch) into the pocket of the lower eyelid.
5 Slowly close the eye for one to two minutes, avoiding blinking, to allow the ointment to spread over the eye surface.

Important Considerations

Since the ointment may cause temporary blurred vision immediately after application, patients should exercise caution and avoid driving or operating machinery until their vision clears completely. If you use other ophthalmic preparations (e.g., eye drops), apply them at least five minutes apart, with the ointment being applied last to ensure maximum retention on the eye surface.

Recent Clinical Evidence

Duratears: Recent Clinical Evidence

Evidence for Temporary Relief of Minor Ocular Irritation and Dry Eye Symptoms

The combination of polymers in Duratears was evaluated in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as minor ocular irritation and certain types of dry eye syndrome. This evidence is derived from Randomized Controlled Trials (RCTs), often patient-masked, which compared the solution against other types of artificial tears or a non-active solution. Research applied in studies examining patient-reported experiences primarily included adult populations diagnosed with mild-to-moderate symptoms.

Outcomes Measured in Clinical Trials

The core research examined how measurements related to patient-reported outcomes describing perceived discomfort were tracked. Trials focused on changes in self-reported scores for symptoms like burning, stinging, or grittiness. In addition to self-reports, researchers also monitored physical signs on the eye's surface, such as the degree of corneal and conjunctival staining.

Studies also monitored functional tear film properties, including Tear Break Up Time (TBUT) and the Schirmer's test. Findings were mixed regarding patterns associated with these functional tear measurements in the research conducted so far.

Long-Term Studies and Follow-up Duration

Clinical trials were conducted during periods of increased symptom activity and were generally designed for the short term. The key RCTs research explored short-term symptom changes over defined time intervals of up to four weeks.

Long-term effects are not fully established for this type of over-the-counter lubricant. There is limited information for long-term outcomes regarding the sustained symptomatic patterns or the overall maintenance of eye health when this solution is used in research exploring how symptoms change over time for periods substantially exceeding the study intervals.

Evidence in Special Populations

The research primarily focused on general adult populations. Research describes specific adult subgroups was observed in some studies, such as trials exploring prevention in high-risk hospitalized patients in the intensive care unit. However, data for certain groups remain insufficient regarding use in pediatric patients and for those with specific comorbidities, as these subgroups are not fully established in the core regulatory research. Results apply only to the populations studied in the trials.

What Remains Uncertain About the Research

Scientific literature suggests that comparative evidence is lacking between this formulation and other ophthalmic lubricants.

Furthermore, when studies explored objective measures of tear function, such as TBUT and tear production, the findings were mixed or inconsistent across the available studies. Evidence quality varies across studies comparing different artificial tears. The research provides insight into short-term changes and highlights what is known — and what is still uncertain.

Key Studies & References

  1. DEXTRAN 70 AND HYPROMELLOSE, UNSPECIFIED (Ophthalmic Solution) [DailyMed Drug Label]
  2. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops
  3. Effect of Nursing Care on Prevention of Dry Eye in Intensive Care Unit Patients (NCT02767258)

Frequently Asked Questions (FAQ)

Common questions about Duratears (FAQ)


Q: What is the difference between Duratears and other eye drops?

A: The official product description indicates that this solution is a combination product utilizing two specific polymers, Dextran 70 and Hypromellose. This dual composition is described in regulatory documents as contributing to the physical stabilization of the tear film and providing lubrication, which differentiates it from eye drops that rely on a single polymer.


Q: Can Duratears be used to treat red eyes?

A: The product is officially indicated for the temporary relief of discomfort and irritation specifically caused by dry eye conditions. Regulatory documents list redness of the eye (hyperaemia) as a possible adverse reaction, not a condition that the medicine is intended to treat.


Q: How quickly does Duratears start working?

A: As an ocular lubricant, the product works by forming a protective film directly on the eye’s surface. Because this is a physical barrier mechanism, the physical effects, such as lubrication, are noted to occur immediately upon application.


Q: How long does the lubrication from Duratears last?

A: Official directions state the product is intended for temporary relief and should be used 'as needed.' This means the duration of the lubrication can vary significantly based on factors like the severity of the user's dry eye condition and the surrounding environment.


Q: Why does Duratears sometimes feel like an ointment instead of a drop?

A: The solution contains the polymer Hypromellose, which is specifically added to increase the product's viscosity, or thickness. This added thickness is intended to contribute to prolonged contact time on the eye, resulting in a feel that may be notably heavier than typical, non-viscous eye drops.


Q: Can I use Duratears every day?

A: This product is classified as a non-prescription lubricant intended for temporary relief and is used as needed. Official documentation advises that long-term effects for this type of over-the-counter product are not fully established in available regulatory data. If symptoms worsen or persist for more than 72 hours, official labeling suggests discontinuing use and seeking consultation.


Q: Why might a doctor prescribe Duratears instead of a standard artificial tear product?

A: Official documents describe this formulation as a dual-polymer combination of Dextran 70 and Hypromellose. This specific pairing is described in regulatory documents as contributing to the physical stabilization of the tear film, which can be a key point of differentiation for this ocular lubricant.


Q: Do I need to shake the Duratears container before use?

A: Official administration instructions for the Dextran 70 and Hypromellose solution do not specify a requirement to shake the container prior to use.


Q: What is the purpose of the liquid paraffin in Duratears?

A: The ointment formulation contains liquid paraffin and white petrolatum. These ingredients contribute to forming an occlusive lipid layer on the eye's surface, which is intended to slow down the rate of tear evaporation.


Q: Can Duratears be used for eyes that water too much?

A: The product's official indication is limited to the temporary relief of minor ocular irritation and discomfort that results from dry eye conditions.


Q: What is the role of mineral oil in the Duratears formulation?

A: In the ointment formulation, mineral oil and other emollients contribute to creating a physical barrier layer on the eye surface. This layer functions as a lubricant to reduce friction and is described as helping to protect against irritation.


Q: Do people with sensitive eyes typically tolerate Duratears?

A: Official documentation indicates that known hypersensitivity (allergy) to any component is a regulatory contraindication. Adverse reactions listed in regulatory data include local effects such as ocular irritation, pain, or redness, which are possibilities noted in the official safety profile.


Q: Are there any specific warnings for people with glaucoma using Duratears?

A: Official regulatory labeling does not contain any specific warnings, contraindications, or precautions that relate to the use of this product by individuals with glaucoma.


Q: Does Duratears contain any preservatives?

A: The inclusion of preservatives depends on the specific packaging of the product. Some multi-dose bottles may contain a preservative, while the single-use unit doses are typically formulated to be preservative-free, according to official inactive ingredient lists.


Q: What is the difference between Duratears Ointment and Duratears Drops?

A: The two forms have different compositions: Duratears Ointment is an oil-based product using ingredients like mineral oil and petrolatum. Duratears Drops (Solution) is an aqueous, or water-based, product that uses the polymers Dextran 70 and Hypromellose.


Q: Is there a maximum number of times per day Duratears can be used?

A: Regulatory instructions direct users to instill the drops 'as needed' for temporary relief. There is no stated maximum frequency per day. However, official safety warnings advise that if eye pain or irritation worsens or persists for more than 72 hours, the official direction is to discontinue use and seek consultation.


Q: Can Duratears be purchased over-the-counter in other countries?

A: Yes, official regulatory bodies in many major international regions consistently classify this product type (Dextran 70/Hypromellose ophthalmic lubricant) as a non-prescription, Human Over-the-Counter drug.


Q: What should I do if Duratears looks cloudy or changes color?

A: The official warning on regulatory labeling advises users not to use the product if the solution changes color or becomes cloudy in appearance. In this circumstance, official requirements state the product must be discarded.


Q: Does Duratears contain electrolytes?

A: Official regulatory documentation listing the inactive ingredients indicates that the formulation includes electrolytes, such as potassium chloride and sodium borate.


Q: Is Duratears oil-based or water-based?

A: The classification depends on the specific product form. The Dextran 70 and Hypromellose drops are classified as an aqueous (water-based) solution, while the ointment version is an oil-based formulation.


Q: What evidence exists about Duratears helping with symptoms from computer use?

A: The official regulatory description of the product's uses notes that it is intended to relieve dry, irritated eyes from common causes. These causes are cited to include extended computer use and reading.

How should Duratears be stored and disposed of?

How to Store and Dispose of Duratears Solution

Duratears (Dextran 70 and Hypromellose Ophthalmic Solution) must be stored at room temperature, typically defined as 15 C to 30 C (59 F to 86 F), or below 25 C. The product must not be frozen and should be protected from light.

Stability and Child Safety

The container must be kept tightly closed after use. For stability purposes, the solution must be discarded four weeks (one month) after first opening. As with all medicines, the bottle must be stored out of the sight and reach of children.

Disposal

Unused or expired solution must be disposed of according to local regulations. The product must not be thrown into wastewater (e.g., sink or toilet) or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duratears found in:

A-Z Index: